Key result
Abciximab reduces death, MI, and urgent TVR in patients with NSTE-ACS.
Key points are not available for this paper at this time.
Supports abciximab in NSTE-ACS care pathways; confirms benefit of GP IIb/IIIa inhibition in high-risk ACS.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Michael Hudson (2006) studied this question. Abciximab reduced death, myocardial infarction, and urgent target vessel revascularization in patients with non-ST-segment elevation acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: